PURPOSE: Determining eligibility for a clinical trial (CT) typically requires a lengthy manual review of data for a single evaluation. The cost associated with eligibility screening is typically not compensated through contracts supporting CTs. METHODS: We used a real-time tracking system that captures CT evaluations and provides information on evaluation outcomes and time spent on each eligibility screening by research staff. Using these data, we describe the effort and costs of eligibility screening overall and per enrolled patient for cancer CTs. The study sample included all completed eligibility assessment (evaluation) records for the 18-month study period. We used generalized multinomial modeling to predict evaluation outcomes and then used the resulting parameter coefficients to estimate the effort associated with each participant, adjusted for probability of being enrolled. From these data, we calculated cost associated with eligibility screening. RESULTS: We found substantial variation in attributed cost by study type and phase. The cost of eligibility screening ranged by study phase from $129.15 to $336.48 per enrolled patient. The estimated annual cost of screening was more than $90,000. CONCLUSION: This study provides results based on prospectively captured effort to estimate the largely nonreimbursed costs of eligibility screening and suggests that screening can be a significant financial burden to an institution. Centers performing CTs may need to acknowledge the differences in screening costs for different study types when negotiating contracts with funding organizations. Information such as that captured here could support such negotiations to reduce the gap between reimbursed and nonreimbursed costs.
PURPOSE: Determining eligibility for a clinical trial (CT) typically requires a lengthy manual review of data for a single evaluation. The cost associated with eligibility screening is typically not compensated through contracts supporting CTs. METHODS: We used a real-time tracking system that captures CT evaluations and provides information on evaluation outcomes and time spent on each eligibility screening by research staff. Using these data, we describe the effort and costs of eligibility screening overall and per enrolled patient for cancer CTs. The study sample included all completed eligibility assessment (evaluation) records for the 18-month study period. We used generalized multinomial modeling to predict evaluation outcomes and then used the resulting parameter coefficients to estimate the effort associated with each participant, adjusted for probability of being enrolled. From these data, we calculated cost associated with eligibility screening. RESULTS: We found substantial variation in attributed cost by study type and phase. The cost of eligibility screening ranged by study phase from $129.15 to $336.48 per enrolled patient. The estimated annual cost of screening was more than $90,000. CONCLUSION: This study provides results based on prospectively captured effort to estimate the largely nonreimbursed costs of eligibility screening and suggests that screening can be a significant financial burden to an institution. Centers performing CTs may need to acknowledge the differences in screening costs for different study types when negotiating contracts with funding organizations. Information such as that captured here could support such negotiations to reduce the gap between reimbursed and nonreimbursed costs.
Authors: Jean G Ford; Mollie W Howerton; Gabriel Y Lai; Tiffany L Gary; Shari Bolen; M Chris Gibbons; Jon Tilburt; Charles Baffi; Teerath Peter Tanpitukpongse; Renee F Wilson; Neil R Powe; Eric B Bass Journal: Cancer Date: 2008-01-15 Impact factor: 6.860
Authors: S Folmar; F Oates-Williams; P Sharp; D Reboussin; J Smith; K Cheshire; J Macer; K Potvin Klein; D Herrington Journal: Control Clin Trials Date: 2001-02
Authors: Paula M Gismondi; Davidson H Hamer; Lynette S Leka; Gerard Dallal; Maria A Fiatarone Singh; Simin N Meydani Journal: J Gerontol A Biol Sci Med Sci Date: 2005-11 Impact factor: 6.053
Authors: Jodie L Robinson; Janene H Fuerch; Dana D Winiewicz; Sarah J Salvy; James N Roemmich; Leonard H Epstein Journal: Prev Med Date: 2007-03-20 Impact factor: 4.018
Authors: Paul C Schroy; Julie T Glick; Patricia Robinson; Maria A Lydotes; Timothy C Heeren; Marianne Prout; Peter Davidson; John B Wong Journal: Clin Trials Date: 2009-11-23 Impact factor: 2.486
Authors: John H Stewart; Alain G Bertoni; Jennifer L Staten; Edward A Levine; Cary P Gross Journal: Ann Surg Oncol Date: 2007-08-08 Impact factor: 5.344
Authors: Holly A Massett; Grace Mishkin; Larry Rubinstein; S Percy Ivy; Andrea Denicoff; Elizabeth Godwin; Kate DiPiazza; Jennifer Bolognese; James A Zwiebel; Jeffrey S Abrams Journal: Clin Cancer Res Date: 2016-07-11 Impact factor: 12.531
Authors: Chaitanya Shivade; Courtney Hebert; Marcelo Lopetegui; Marie-Catherine de Marneffe; Eric Fosler-Lussier; Albert M Lai Journal: J Biomed Inform Date: 2015-09-14 Impact factor: 6.317
Authors: Judith W Dexheimer; Huaxiu Tang; Andrea Kachelmeyer; Melanie Hounchell; Stephanie Kennebeck; Imre Solti; Yizhao Ni Journal: Pediatr Emerg Care Date: 2019-12 Impact factor: 1.454
Authors: Valentina I Petkov; Lynne T Penberthy; Bassam A Dahman; Andrew Poklepovic; Chris W Gillam; James H McDermott Journal: Exp Biol Med (Maywood) Date: 2013-10-09
Authors: Alison Callahan; Vladimir Polony; José D Posada; Juan M Banda; Saurabh Gombar; Nigam H Shah Journal: J Am Med Inform Assoc Date: 2021-07-14 Impact factor: 4.497
Authors: Emily C O'Brien; Sudha R Raman; Alicia Ellis; Bradley G Hammill; Lisa G Berdan; Tyrus Rorick; Salim Janmohamed; Zachary Lampron; Adrian F Hernandez; Lesley H Curtis Journal: Trials Date: 2021-07-19 Impact factor: 2.279